Beam Therapeutics (BEAM) Leases: 2019-2025
Historic Leases for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $97.0 million.
- Beam Therapeutics' Leases fell 7.36% to $97.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.0 million, marking a year-over-year decrease of 7.36%. This contributed to the annual value of $104.9 million for FY2024, which is 7.07% down from last year.
- Beam Therapeutics' Leases amounted to $97.0 million in Q3 2025, which was down 2.58% from $99.6 million recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Leases registered a high of $118.5 million during Q4 2022, and its lowest value of $13.6 million during Q2 2022.
- Moreover, its 3-year median value for Leases was $106.9 million (2024), whereas its average is $107.2 million.
- Per our database at Business Quant, Beam Therapeutics' Leases spiked by 2,442.71% in 2021 and then crashed by 87.09% in 2022.
- Over the past 5 years, Beam Therapeutics' Leases (Quarterly) stood at $102.7 million in 2021, then rose by 15.38% to $118.5 million in 2022, then fell by 4.78% to $112.8 million in 2023, then declined by 7.07% to $104.9 million in 2024, then fell by 7.36% to $97.0 million in 2025.
- Its Leases was $97.0 million in Q3 2025, compared to $99.6 million in Q2 2025 and $102.2 million in Q1 2025.